This paper reviews the current status of conservative treatment for early breast cancer. While the first patients were treated with such techniques more than 60 years ago, it is during the last decade that randomized trials have confirmed that such treatment is comparable to mastectomy in preventing breast cancer death. Radiotherapy to the breast after local tumour excision is important to prevent local breast relapse, but it is not clear whether it has any influence on the risk of distant metastases. Several questions remain to be answered. While most investigators agree that the breast should receive a radiation dose of about 50Gy in 5 weeks, there is no general agreement about the need for a tumour bed booster dose. Considering patients with tumour infiltration at the surgical resection line for whom it is not possible for cosmetic reasons to perform re-resection, it is not clear whether an acceptable local control rate can be achieved through application of a high booster dose in the tumour bed. More trials are needed to show whether certain patients with small invasive carcinomas should be treated with wide local excision without radiotherapy. The need for radiotherapy after local excision for small intraductal (ductal carcinoma in situ) cancers is being addressed in ongoing trials.Key words: Breast cancer, breast conserving therapy, local relapse risk, review.The term 'breast-conserving treatment' includes techniques by which radical eradication of an early breast cancer (TI -2, NO-I, MO) is achieved without ablation of the mammary gland. Such treatment techniques have attracted widespread interest and recently become accepted alternatives to more radical and mutilating surgical procedures. The possibility of treating limited breast cancers, without breast ablation was suggested more than 60 years ago. Hirsch. (1) in Berlin and Keynes (2) in London published their first results in 1927 and 1929 respectively. Mustakallio (3) in Helsinki published his first series in 1945, and the Institute Curie group headed by Baclesse published their results in 1949 (4). The preliminary results achieved by these pioneers suggested that survival after breastconserving treatment could be similar to that achieved after radical mastectomy. This view gained further support when a follow-up paper from St. Bartholomew's Hospital (5) in 1953 reported long-term survival to be similar among the patients treated conservatively by Keynes and breast cancer patients treated in the same hospital with mastectomy. During the 1960s more authors reported encouraging results with breast-conserving treatment (6-9). and during the last two decades multiple reports have been published:1. The survival rate and risk of distant metastases following breastconserving therapy and mastectomy have been compared in randomized trials. 2.Long-term ( > 25 years) follow-up reports containing large numbers of patients have provided important information on long-term survival and risk of locoregional failure. These studies also give important informat...
Mammakarzinome konnen zur Zeit nur geheilt werden, wenn sie fruhzeitig diagnostiziert und vollstandig entfernt werden. Fall- 20,32) sowie randomisierte klinische Studien (5, 26, 30) lassen den SchluB zu, daB die Mortalitat a n Brustkrebs reduziert werden konnte, wenn die Mammographie als Vorsorgeuntersuchung angeboten und wahrgenommen wiirde. Deshalb fordert die >>American Cancer Societycc fur 40-bis 49jahrige Frauen alle 1-2 Jahre und a b dem 50. Lebensjahr jahrliche Mammographien (10). Daruber hinaus empfiehlt die Deutsche Krebshilfe eine Mammographie etwa im 30. Lebensjahr als Ausgangsbefund und jahrliche Mammographien auch bei jungeren Frauen mit erhohtem Brustkrebsrisiko (Ubersicht: 12).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.